Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies?
Syed Z A
SZ
Zaidi
Mahmoud
M
Aljurf
D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D016527:Drug Costs; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control*; D007938:Leukemia / Q000150:complications* / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000188:drug therapy*; D011994:Recombinant Proteins; D015275:Tumor Lysis Syndrome / Q000209:etiology / Q000517:prevention & control*; D014503:Urate Oxidase / Q000008:administration & dosage / Q000627:therapeutic use*
D011994:Recombinant Proteins; C469709:rasburicase; D014503:Urate Oxidase